About the CEO

Dr. Thomas R. Caulfield is the Founder and Chief Executive Officer of Digital Ether Computing, where he is pioneering new architectures of artificial intelligence to transform drug discovery, functional genomics, and the future of molecular medicine. His vision is to create adaptive intelligence systems that not only accelerate the development of therapies but also redefine how knowledge itself is structured and applied to human health.

Under his leadership, Digital Ether Computing has introduced breakthrough platforms that embody this mission: Liquid Adaptive AI, a continuously self-modifying reasoning system designed to learn and adapt in real time; the Dynamicasome, a genomic atlas capturing the structural and functional consequences of every missense mutation; LC-JT-VAE, a generative molecular design engine that produces highly accurate drug candidates; and Nexomorphs, a first-in-class category of therapeutics capable of reprogramming disease biology. Together, these technologies position the company at the frontier of AI, biology, and medicine.

Dr. Caulfield brings to this role a distinguished scientific career. As Director of the Drug Discovery, Design and Optimization Laboratory at Mayo Clinic, he led programs for more than a decade that generated over 65 patents, authored 110+ peer-reviewed publications, and advanced multiple compounds into Phase I clinical trials. His discoveries have been translated into collaborations with global pharmaceutical companies and have been featured in leading journals, including Nature Communications Biology, Science Advances, Biomolecules, and AI.

He holds a B.S. in Physics (Mathematics), an M.S. in Chemistry, and a Ph.D. in Chemistry/Biophysics from Georgia Tech, with postdoctoral research at Roche, UC San Diego, and TPIMS, followed by a fellowship at Mayo Clinic.

Driven by a personal mission to apply AI as a transformative force for humanity, Dr. Caulfield is building Digital Ether Computing into a company that redefines the boundaries of medicine while laying the foundations for adaptive intelligence across society.

Ryan King, CMC (Ret.), is the Chief Operating Officer of Digital Ether Computing, where he oversees operational strategy, partnerships, and execution of the company’s AI-driven drug discovery programs. A retired Navy officer with more than 25 years of leadership experience, Ryan brings deep expertise in managing complex organizations and delivering mission-critical results.

As COO, he drives the alignment of Digital Ether Computing’s scientific innovations with business operations, ensuring the company’s breakthrough platforms, including Liquid Adaptive AI, the Dynamicasome, and LC-JT-VAE, are positioned for real-world translation. His leadership supports investor relations, strategic collaborations, and the scaling of operations from research into therapeutic pipelines.

Ryan’s Navy career included roles in command, logistics, and operational planning, where he earned a reputation for disciplined execution and organizational excellence. He has successfully transitioned these skills to the biotech and AI sector, helping Digital Ether Computing establish key industry and academic partnerships while navigating the fast-moving startup landscape.

With his combination of military precision and entrepreneurial drive, Ryan ensures the company’s vision of transforming medicine through adaptive AI is backed by sound operational and financial strategy.

Alex Baker, PhD, is the Chief Science Officer of Digital Ether Computing, where he leads the company’s scientific strategy, platform integration, and translational research programs. With extensive experience in molecular pharmacology, assay development, and drug discovery, Alex bridges the gap between Digital Ether Computing’s adaptive AI platforms and their application to real-world therapeutic pipelines.

As CSO, he directs the validation of compounds generated by Liquid Adaptive AI, the Dynamicasome, and LC-JT-VAE, ensuring that discoveries are rigorously tested and advanced toward preclinical and clinical milestones. His leadership strengthens the company’s ability to turn pioneering AI-driven models into tangible therapies that address urgent unmet medical needs.

Alex’s career spans both academic and industry settings, where he has established a reputation for building innovative platforms that connect computational discovery with experimental validation. He has developed assays for molecular glues, targeted protein degradation, and next-generation therapeutics, providing critical expertise to accelerate Digital Ether Computing’s research and development.

By combining scientific rigor with an entrepreneurial mindset, Alex ensures that the company’s vision of transforming medicine with adaptive AI is anchored in strong experimental evidence and positioned for impact across oncology, neurology, and other major disease areas.